Base Genomics Raises $11M in Seed Funding

Base Genomics, a UK-based epigenetics company, has secured $11 million in seed funding led by Oxford Sciences Innovation. The company will use the funds to progress development of its TAPS technology, focusing on creating a blood test for early-stage cancer and minimal residual disease. Base Genomics' TAPS technology offers a novel approach to DNA methylation sequencing, providing advantages over traditional methods.

Base Genomics Raises $11 Million to Develop Blood Test for Early Cancer Detection

Base Genomics, an Oxford, England, UK-based epigenetics company, has developed TAPS (TET-assisted pyridine borane sequencing), a new invention to sequence DNA methylation developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford. TAPS is a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike bisulfite sequencing, TAPS does not degrade DNA, meaning that more DNA is available for sequencing. It also retains sequence complexity, cutting sequencing costs and enabling simultaneous epigenetic and genetic analysis.

Base Genomics is an epigenetics company developing TAPS, a new technology to sequence DNA methylation, enabling more efficient and cost-effective genomic analysis.

5 years ago

Base Genomics Raises $11 Million to Develop Blood Test for Early Cancer Detection

ProblemHealthcare

Solution

Covered on